9 results
* to describe the safety profile for qW, q2W and q3W regimens. * to determine the Maximum Tolerated Dose (MTD), if achieved (all regimens)* to describe the pharmacokinetics (PK) of single-agent RO6895882. Substudy BP28920/IMGThe study is designed to…
One of the he questions that remains to be answered to further elucidate the mechanism of action is whether ot not UAG improves insulin sensitivity during a euglycemis-hyperinsulinemic clampThis study aims to clarify the effects of the continuous…
Two key questions remain to be answered to further elucidate the mechanism of action: 1) is the effect on glucose metabolism dose dependent in Type 2 diabetes patients? and 2) Does UAG decrease glucose concentrations during an oral glucose loadThis…
The aim of this study is to improve clinical outcomes in patients with insulin-treated DM after coronary stent placement in the treatment of coronary artery disease with drug-eluting balloon therapy after stent placement.
Study BP29541 is a first in-human, open-label, multicenter, dose-escalation Phase I clinical study of single-agent RO6958688. The study will be conducted in two parts. Part I of the study is single ascending dose in single patient cohorts to…
1. To determine the change in plaque characteristics of non-culprit LRPs, as measured with IVUS/NIRS, after treatment with DEB in patients with ACS.2. To develop a non-invasive algorithm that is able to detect LRPs with CT.
To determine the change in plaque characteristics after treatment with DEB of additional LRPs, as measured by IVUS / NIRS, in ACS patients.
The primary objective of the study is to evaluate the efficacy of obinutuzumab(GA101) plus venetoclax (GVe) versus standard chemoimmunotherapy (BR/FCR)[concerning MRD negativity measured by flow cytometry in peripheral blood (PB)at month 15] and…
Assess the potential efficay of L-serine dietary supplementation in patients children with a GRIN2B LoS mutation.